BCL10 Mouse Monoclonal Antibody [Clone ID: OTI4A8]

CAT#: TA400004

Anti-BCL10 mouse mAb, clone OTI4A8, PE conjugated

Conjugation: Unconjugated Biotin HRP PE



  View other "OTI4A8" antibodies (5)

Need it in bulk or conjugated?
Get a free quote

CNY 3,790.00


货期*
4周

规格
    • 100 ul

Product images

Specifications

Product Data
Clone Name OTI4A8
Applications FC
Recommend Dilution FC 1:50
Reactivity Human
Host Mouse
Clonality Monoclonal
Immunogen Full length human recombinant protein of human BCL10 (NP_003912) produced in HEK293T cell.
Formulation PBS (pH7.4) containing 0.02% NaN3; store at 4C, do not freeze
Concentration 0.5 mg/ml
Purification Purified from mouse ascites fluids by affinity chromatography
Conjugation PE
Storage Condition Store at 4°C.
Predicted Protein Size 26.1 kDa
Gene Name BCL10 immune signaling adaptor
Background This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.
Synonyms c-E10; CARMEN; CIPER; CLAP; IMD37; mE10
Reference Data
Protein Families Druggable Genome
Protein Pathways B cell receptor signaling pathway, T cell receptor signaling pathway
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Other Versions

Customer Reviews 
Loading...